• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Neurotech International

Neurotech International

ASX:NTI

  • Home
  • Corporate
    • Board and Management
    • Corporate Directory
    • Corporate Governance
  • Development Programs
    • Biopharmaceutical Trials
    • Combination Therapy
    • Pathways to Commercialisation
    • Mente Technology
  • Investors
    • Investor Dashboard
    • ASX Announcements
    • Company Reports
    • Presentations
    • Research
    • News & Media
  • Contact

News &
Media

  • Webinar Recap – NTI, MHK, RPM & ESK

    6 June 2022
    Sharecafe
    View More
  • Australia’s top 20 cannabis companies

    26 May 2022
    Business News Australia

    A report from FreshLeaf Analytics forecasts Australian medicinal cannabis sales of $423 million for 2022, up from an estimated $230 million in 2021. As prices for practically everything rose last year, medicinal cannabis prices went down on average, opening up more budgets to treatment.

    View More
  • Neurotech International (ASX:NTI) appoints Alexandra Andrews as CEO

    3 March 2022
    The Market Herald

    Dr Andrews has experience in corporate development, investor engagement, product development and commercialisation, clinical trials and regulatory environments.

    She has a Doctor of Philosophy in Neuroscience from the University of Western Australia.

    View More
  • Neurotech International Phase I/II Autism Results Due this Quarter

    6 October 2021
    Bioshares

    In July last year Neurotech International (NTI: $0.05) acquired a license from Dolce CannGroup for access to specific proprietary strains of cannabis for the potential treatment of various neurological conditions.

    View More
  • Neurotech International (ASX:NTI) Is In A Good Position To Deliver On Growth Plans

    4 September 2021
    Simply Wall St
    View More
  • From Backstreet to Highstreet: How Cannabis Has Entered the Mainstream

    18 August 2021
    The Market Herald

    Explore the $31.96 billion global cannabis market that is disrupting the healthcare and pharmaceutical industries.

    View More
  • Australia’s Neurotech Inks Cannabis Cultivation Partnership

    11 May 2021
    The Hemp Gazette

    Neurotech International Limited (ASX:NTI) has established a strategic medical cannabis cultivation partnership with CannaPacific Limited.

    View More
  • Neurotech just started world’s first THC-less cannabis study in autistic children

    6 May 2021
    Stockhead

    The Phase I/II clinical trial announced today is a groundbreaking study where medicinal cannabis containing little to no THC is being tested on autistic children.

    View More
  • Neurotech embarks on ground-breaking ASD trials

    5 May 2021
    Finfeed

    Neurotech International Limited (ASX:NTI) has commenced a Phase I/II open label clinical study in 20 children aged between 5-17 years with Autism Spectrum Disorder (ASD).

    View More
Previous
1 … 3 4 5 6
Next

Footer

Suite 5 CPC, 145 Stirling Highway
Nedlands WA 6009
Australia

moc.l1685458175anoit1685458175anret1685458175nihce1685458175torue1685458175n@ofn1685458175i1685458175

+61 (8) 9389 3130

Subscribe to our latest announcements

Name*
This field is for validation purposes and should be left unchanged.

Copyright © 2023 Neurotech International • Site by White Noise Communications

Download prospectus